// App-Quantinova.ai

S4424 2015 AHA : Improved Assessment of CAD in Women with Flurpiridaz F-18 PET Myocardial Perfusion Imaging: Results of Subset Analysis of the Flurpiridaz F-18 Phase 3 Study

Researchers

Presenter

  • Jamshid Maddahi

Principal Investigators

  • James E Udelson

  • Robert Beanlands

  • Juhani Knuuti

  • Timothy M Bateman

  • Daniel S Berman

  • Joel Lazewatsky

  • Cesare Orlandi

Medical Centers

  • Ottawa Heart Inst, Ottawa, ON, Canada

  • Saint Lukes Mid America Heart Institute, Kansas City, MO

  • Turku Univ Hosp, Turku, Finland

  • Morristown Medical Center, Morristown, NJ

  • Lantheus Medical Imaging, Billerica, MA

  • Cedars-Sinai Medical Center, Los Angeles, CA

  • Tufts Medical Center, Boston, MA

  • UCLA Medcl Ctr, Los Angeles, CA

Locations

  • United States

  • Canada

  • Finland

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Coronary Artery Disease

Biomarkers

  • Secretory Leukocyte Peptidase Inhibitor

  • Body mass index

Drug/Treatment

  • flurpiridaz F 18

Outcome

  • N/A

Study Design

  • non inferiority

  • superiority

  • double blind/blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved